70% of Nepal's population developed Covid antibodies, finds study
prevalence of coronavirus in communities, and help authorities prepare strategies for locating hotspots and taking necessary measures to contain the spread of the virus.
Such a study can also tell authorities how many people in a specific population may have
contracted the virus.The ministry said that it carried out the seroprevalence test from July 5 to August 14 and blood samples of 13, 161 individuals were analysed.The antibodies were found in all age groups, all kinds of geographies, professions, and sexes.The ministry also assessed the efficacy of Covid vaccine during the study. Those people who had received only one dose of vaccine have developed 80 per cent antibodies against Covid while those who were inoculated with both doses developed 90 per cent antibodies.With these studies, Covid vaccines are found very effective against the Covid-19, the ministry said. Nepal has been administering various kinds of the Covid vaccine developed by different companies. Initially, ot began using Covishield, manufactured by the Serum Institute of India, and then Vero Cell produced by China's Sinopharm, J&J of the US, the AstraZeneca vaccine made in Japan. The highest number of people have received China's Vero Cell.As of Monday (August 23), the country has received 13,227,590 doses of vaccines - of AstraZeneca, Vero Cell and Janssen. Nepal launched its vaccination campaign on January 27 with 1 million doses of Covishield received in grant assistance from India. Nepal on Sunday reported 1,214 new coronavirus cases in the last 24 hours taking the nationwide infection tally to 759,222.The countrywide death toll has now reached 10,714. The number of active cases stands at 35,796.According to the ministry, 712,712 infected people have recovered from the disease so far.
--IANS giri/vd